EA200001109A1 - Новые частицы, композиция на их основе и способ лечения с их применением - Google Patents
Новые частицы, композиция на их основе и способ лечения с их применениемInfo
- Publication number
- EA200001109A1 EA200001109A1 EA200001109A EA200001109A EA200001109A1 EA 200001109 A1 EA200001109 A1 EA 200001109A1 EA 200001109 A EA200001109 A EA 200001109A EA 200001109 A EA200001109 A EA 200001109A EA 200001109 A1 EA200001109 A1 EA 200001109A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- basis
- application
- treatment
- composition
- mammals
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
Abstract
Настоящее изобретение предлагает носители, способные доставлять высокие концентрации слабо гидрофильных и слабо липофильных соединений в организм млекопитающих путем комбинирования соединений, имеющих биологически совместимые гидрофобные области с конъюгатами, имеющими как гидрофобные, так и гидрофильные области. Указанные композиции могут найти ряд применений у млекопитающих, в частности для введения им высоких концентраций терапевтически активных соединений, не оказывая при этом нежелательного уровня побочных эффектов.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8610898P | 1998-05-20 | 1998-05-20 | |
PCT/US1999/010975 WO1999059550A1 (en) | 1998-05-20 | 1999-05-19 | Novel particulate formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200001109A1 true EA200001109A1 (ru) | 2001-06-25 |
Family
ID=22196324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200001109A EA200001109A1 (ru) | 1998-05-20 | 1999-05-19 | Новые частицы, композиция на их основе и способ лечения с их применением |
Country Status (18)
Country | Link |
---|---|
US (1) | US6500461B2 (ru) |
EP (1) | EP1079812A4 (ru) |
JP (1) | JP2002535242A (ru) |
KR (1) | KR20010052368A (ru) |
CN (1) | CN1310612A (ru) |
AR (1) | AR019308A1 (ru) |
AU (1) | AU745015B2 (ru) |
BR (1) | BR9911031A (ru) |
CA (1) | CA2332545A1 (ru) |
EA (1) | EA200001109A1 (ru) |
EE (1) | EE200000693A (ru) |
ID (1) | ID28166A (ru) |
IL (1) | IL139541A0 (ru) |
NO (1) | NO20005832L (ru) |
PL (1) | PL344327A1 (ru) |
SK (1) | SK17422000A3 (ru) |
TR (1) | TR200003435T2 (ru) |
WO (1) | WO1999059550A1 (ru) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US8067032B2 (en) * | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
US6977085B2 (en) * | 2000-12-22 | 2005-12-20 | Baxter International Inc. | Method for preparing submicron suspensions with polymorph control |
US20040022862A1 (en) * | 2000-12-22 | 2004-02-05 | Kipp James E. | Method for preparing small particles |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
EP1429749A2 (en) | 2001-09-26 | 2004-06-23 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
US7241456B2 (en) * | 2002-10-25 | 2007-07-10 | Australian Importers Ltd. | Formulations for topical delivery of bioactive substances and methods for their use |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7553810B2 (en) | 2004-06-16 | 2009-06-30 | Pneumrx, Inc. | Lung volume reduction using glue composition |
US7678767B2 (en) | 2004-06-16 | 2010-03-16 | Pneumrx, Inc. | Glue compositions for lung volume reduction |
US7608579B2 (en) | 2004-06-16 | 2009-10-27 | Pneumrx, Inc. | Lung volume reduction using glue compositions |
US20050281740A1 (en) * | 2004-06-16 | 2005-12-22 | Glen Gong | Imaging damaged lung tissue |
US7468350B2 (en) | 2004-06-16 | 2008-12-23 | Pneumrx, Inc. | Glue composition for lung volume reduction |
WO2006014567A2 (en) | 2004-07-08 | 2006-02-09 | Pneumrx, Inc. | Pleural effusion treatment device, method and material |
WO2006014626A2 (en) | 2004-07-19 | 2006-02-09 | Celator Pharmaceuticals, Inc. | Partuculate constructs for release of active agents |
BRPI0600285C1 (pt) * | 2006-01-13 | 2011-10-11 | Brz Biotecnologia Ltda | compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas |
WO2008141230A1 (en) | 2007-05-09 | 2008-11-20 | Lawrence Livermore National Security, Llc | Methods and systems for monitoring production of a target protein in a nanolipoprotein particle |
CA2693377A1 (en) | 2007-07-21 | 2009-01-29 | Albany Molecular Research, Inc. | 5-pyridinone substituted indazoles |
WO2009049089A1 (en) | 2007-10-09 | 2009-04-16 | Washington University In St. Louis | Ligand directed toroidal nanoparticles for therapy and diagnostic imaging |
WO2009049083A1 (en) | 2007-10-09 | 2009-04-16 | Washington University In St. Louis | Particles for imaging |
JP2011504505A (ja) | 2007-11-21 | 2011-02-10 | デコード ジェネティクス イーエイチエフ | 肺および心血管障害を治療するためのビアリールpde4抑制剤 |
EP2240481A1 (en) | 2008-01-11 | 2010-10-20 | Albany Molecular Research, Inc. | (1-azinone) -substituted pyridoindoles as mch antagonists |
EP2344134B1 (en) * | 2008-09-23 | 2017-11-08 | The Regents of The University of California | Nanocarriers for drug delivery |
WO2010059836A1 (en) | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Substituted aza-bridged bicyclics for cardiovascular and cns disease |
BRPI1007350B8 (pt) | 2009-01-26 | 2021-05-25 | Israel Institute For Biological Res | compostos espiro heterocíclicos bicíclicos |
CN101670095B (zh) * | 2009-04-13 | 2012-05-23 | 北京大学 | 一种用于栓塞治疗的药物组合物及其制备方法 |
US8710046B2 (en) | 2009-07-14 | 2014-04-29 | Albany Molecular Research, Inc. | 5-HT3 receptor modulators, methods of making, and use thereof |
JP2013514999A (ja) | 2009-12-17 | 2013-05-02 | ワシントン・ユニバーシティ | 抗血栓性ナノ粒子 |
US9808500B2 (en) | 2009-12-17 | 2017-11-07 | Washington University | Antithrombotic nanoparticle |
TWI438009B (zh) * | 2010-02-19 | 2014-05-21 | Teikoku Pharma Usa Inc | 紫杉烷前-乳劑調配物及其製造與使用之方法 |
EP2558072B1 (en) | 2010-04-15 | 2018-09-26 | The Washington University | Prodrug compositions, prodrug nanoparticles, and methods of use thereof |
KR101752944B1 (ko) | 2010-05-03 | 2017-07-03 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 비수성의 탁산 프로에멀젼 제제, 및 그의 제조 및 사용 방법 |
US8895055B2 (en) | 2011-12-21 | 2014-11-25 | The Regents Of The University Of California | Telodendrimer nanodiscs without apolipoprotein |
US9644038B2 (en) | 2011-12-21 | 2017-05-09 | The Regents Of The University Of California | Apolipoprotein nanodiscs with telodendrimer |
JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
US9642916B2 (en) | 2012-12-12 | 2017-05-09 | The Regents Of The University Of California | Porphyrin modified telodendrimers |
US11279749B2 (en) | 2015-09-11 | 2022-03-22 | Lawrence Livermore National Security, Llc | Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation |
EP3512569A4 (en) | 2016-09-15 | 2020-09-23 | The Regents of The University of California | ENHANCED HYBRID TELODENDRIMERS |
US11207422B2 (en) | 2017-05-02 | 2021-12-28 | Lawrence Livermore National Security, Llc | MOMP telonanoparticles, and related compositions, methods and systems |
CA3093340A1 (en) | 2018-03-20 | 2019-09-26 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
AU2019419414A1 (en) | 2018-12-31 | 2023-04-06 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8601100D0 (en) * | 1986-01-17 | 1986-02-19 | Cosmas Damian Ltd | Drug delivery system |
MX9203504A (es) * | 1988-04-20 | 1992-07-01 | Liposome Co Inc | Complejo agente: lipido activo de alta proporcion. |
JP2687448B2 (ja) * | 1988-06-22 | 1997-12-08 | 大正製薬株式会社 | イブプロフェン徐放性製剤 |
JPH0429924A (ja) * | 1990-05-28 | 1992-01-31 | Terumo Corp | 脂溶性薬物含有注射用製剤 |
WO1991019486A1 (en) | 1990-06-14 | 1991-12-26 | Kalmo Enterprises, Inc. | Stable aqueous drug suspensions |
US5599556A (en) * | 1991-12-31 | 1997-02-04 | Abbott Laboratories | Prolamine coatings for taste masking |
ES2173096T3 (es) | 1992-08-05 | 2002-10-16 | Faulding F H & Co Ltd | Composicion farmaceutica peletizada. |
US5346702A (en) * | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US5776486A (en) * | 1993-05-28 | 1998-07-07 | Aphios Corporation | Methods and apparatus for making liposomes containing hydrophobic drugs |
US5478860A (en) | 1993-06-04 | 1995-12-26 | Inex Pharmaceuticals Corp. | Stable microemulsions for hydrophobic compound delivery |
US5565215A (en) * | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
US5415869A (en) | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
CN1100770C (zh) * | 1995-09-12 | 2003-02-05 | 利普索姆公司 | 促进水解的紫杉烷疏水性衍生物 |
HRP970493A2 (en) | 1996-09-23 | 1998-08-31 | Wienman E. Phlips | Oral delayed immediate release medical formulation and method for preparing the same |
-
1999
- 1999-05-19 ID IDW20002634A patent/ID28166A/id unknown
- 1999-05-19 PL PL99344327A patent/PL344327A1/xx unknown
- 1999-05-19 CA CA002332545A patent/CA2332545A1/en not_active Abandoned
- 1999-05-19 EA EA200001109A patent/EA200001109A1/ru unknown
- 1999-05-19 JP JP2000549215A patent/JP2002535242A/ja active Pending
- 1999-05-19 CN CN99808935A patent/CN1310612A/zh active Pending
- 1999-05-19 US US09/314,338 patent/US6500461B2/en not_active Expired - Fee Related
- 1999-05-19 IL IL13954199A patent/IL139541A0/xx unknown
- 1999-05-19 WO PCT/US1999/010975 patent/WO1999059550A1/en not_active Application Discontinuation
- 1999-05-19 TR TR2000/03435T patent/TR200003435T2/xx unknown
- 1999-05-19 KR KR1020007013002A patent/KR20010052368A/ko not_active Application Discontinuation
- 1999-05-19 EP EP99925661A patent/EP1079812A4/en not_active Withdrawn
- 1999-05-19 BR BR9911031-8A patent/BR9911031A/pt not_active IP Right Cessation
- 1999-05-19 AR ARP990102392A patent/AR019308A1/es unknown
- 1999-05-19 EE EEP200000693A patent/EE200000693A/xx unknown
- 1999-05-19 SK SK1742-2000A patent/SK17422000A3/sk unknown
- 1999-05-19 AU AU41906/99A patent/AU745015B2/en not_active Ceased
-
2000
- 2000-11-17 NO NO20005832A patent/NO20005832L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2002535242A (ja) | 2002-10-22 |
EP1079812A4 (en) | 2001-12-12 |
NO20005832D0 (no) | 2000-11-17 |
AR019308A1 (es) | 2002-02-13 |
IL139541A0 (en) | 2004-02-08 |
CN1310612A (zh) | 2001-08-29 |
SK17422000A3 (sk) | 2001-09-11 |
ID28166A (id) | 2001-05-10 |
TR200003435T2 (tr) | 2001-03-21 |
US6500461B2 (en) | 2002-12-31 |
EP1079812A1 (en) | 2001-03-07 |
KR20010052368A (ko) | 2001-06-25 |
AU4190699A (en) | 1999-12-06 |
BR9911031A (pt) | 2002-01-29 |
CA2332545A1 (en) | 1999-11-25 |
EE200000693A (et) | 2002-04-15 |
NO20005832L (no) | 2001-01-18 |
WO1999059550A1 (en) | 1999-11-25 |
US20020034536A1 (en) | 2002-03-21 |
PL344327A1 (en) | 2001-10-22 |
AU745015B2 (en) | 2002-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200001109A1 (ru) | Новые частицы, композиция на их основе и способ лечения с их применением | |
BR0111126A (pt) | Derivados de aminoácidos cìclicos úteis como agentes farmacêuticos | |
ATE324907T1 (de) | Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen | |
PL316942A1 (en) | Novel pharmaceutic compositions based on taxoides | |
CA2366702A1 (en) | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents | |
BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
EP0693924A4 (en) | METHODS OF ADMINISTRATION -i (IN VIVO) OF BIOLOGICAL SUBSTANCES AND COMPOSITIONS USED IN SUCH METHODS | |
EA200400962A1 (ru) | Полиалкиленгликоль с остатком для конъюгации биологически активного соединения | |
DE69833684D1 (de) | Antioxidierende stabilisierungssysteme für pharmazeutische formulierungen | |
FI971776A (fi) | Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi | |
EA200000594A1 (ru) | Новые макролиды | |
HRP20020787B1 (en) | Method of treatment using ligand-immunogen conjugates | |
DE69622157T2 (de) | Zusammensetzung zur verhinderung von osteolyse und metastasen | |
ES2133324T3 (es) | Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso. | |
ATE315407T1 (de) | Verbindungen mit einer sulfonamidgruppe und diese verbindungen enthaltende pharmazeutische zusammensetzungen | |
EA200500300A1 (ru) | Цитотоксические агенты, содержащие новые сильнодействующие таксаны, и их терапевтическое применение | |
NO20041059L (no) | Kombinasjon av utvalgte opioder med muskarinantagonister for behandling av urininkontinens | |
DE69805983D1 (de) | Hustenhemmende, theobromine enthaltende zusammensetzungen | |
EA199901012A1 (ru) | Фармацевтические композиции на основе тизоксанида и нитазоксанида | |
ATE297217T1 (de) | Zusammensetzung zur vorbeugung und behandlung von transplantatabstossung | |
PE20030303A1 (es) | FORMULACIONES DE INTERFERON ß HUMANO | |
BR9908838A (pt) | Uso de um glicocorticóide, processeo para tratar glomerulonefrite aguda ou crÈnica, e, composição farmacêutica para tratar glomerulonefrite | |
DK1100463T3 (da) | Injicerbare formuleringer indeholdende ramoplanin |